## Gene Summary
PPARG (Peroxisome Proliferator Activated Receptor Gamma) is a gene that encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear hormone receptors. PPARG primarily functions as a regulator of adipocyte differentiation and glucose homeostasis. It is widely expressed in tissues like adipose tissue, colon, and macrophages. PPARG plays a pivotal role in lipid metabolism, insulin sensitivity, and the modulation of inflammation.

## Gene Drugs, Diseases, Phenotypes, and Pathways
PPARG is closely associated with the pathology of several metabolic disorders, primarily type 2 diabetes and obesity. It is also implicated in the regulation of lipid and lipoprotein metabolism, as well as in the pathogenesis of cardiovascular diseases. PPARG interacts with numerous pathways, including lipid metabolism and inflammation pathways. The activation of PPARG influences various phenotypes related to metabolic syndrome, including insulin sensitivity and body fat distribution. 

## Pharmacogenetics
PPARG is a major pharmacological target for the management of type 2 diabetes and other aspects of the metabolic syndrome. Thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, are direct agonists of PPARG and widely used in clinical practice to improve insulin sensitivity. The effectiveness and safety of these drugs can vary based on genetic polymorphisms in the PPARG gene. Several studies have shown that specific variants, such as the well-studied Pro12Ala polymorphism, significantly influence the therapeutic response and risk profiles for TZDs, involving aspects like weight gain and edema. The pharmacogenetic effects of PPARG variants can thus guide personalized treatment approaches in managing diabetes and potentially reduce associated risks.